UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

 

Filed by the Registrant                                Filed by a Party other than the Registrant  

Check the appropriate box:

 

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Under Rule 14a-12

Albireo Pharma, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

1)

Title of each class of securities to which transaction applies:

 

 

2)

Aggregate number of securities to which transaction applies:

 

 

3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

 

4)

Proposed maximum aggregate value of transaction:

 

 

5)

Total fee paid:

 

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing:

 

1)

Amount previously paid:

 

 

2)

Form, Schedule or Registration Statement No:

 

 

 

 

3)

Filing party:

 

 

4)

Date Filed:

 

 

 

 


BARCODE See the reverse side of this notice to obtain proxy materials and voting instructions. BROKER LOGO HERE 1 OF 2 12 15 1234567 1234567 1234567 1234567 1234567 1234567 1234567 Broadridge Internal Use Only Job # Envelope # Sequence # # of # Sequence # *** Exercise Your Right to Vote *** Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on <mtgdate>. You are receiving this communication because you hold shares in the above named company. This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side). We encourage you to access and review all of the important information contained in the proxy materials before voting. Meeting Information Meeting Type: <mtgtype> For holders as of: <recdate> Date: Time: <mtgtime> Location: 0000335536_1 R1.0.1.15 ALBIREO PHARMA INC. Annual Meeting June 09, 2017 June 09, 2017 8:30 AM EDT April 18, 2017 Albireo Pharma, Inc. 10 Post Office Square Suite 502 South Boston, MA 02109 Return Address Line 1 Return Address Line 2 Return Address Line 3 51 MERCEDES WAY EDGEWOOD NY 11717 Investor Address Line 1 Investor Address Line 2 Investor Address Line 3 Investor Address Line 4 Investor Address Line 5 John Sample 1234 ANYWHERE STREET ANY CITY, ON A1A 1A1


How To Vote Please Choose One of the Following Voting Methods Internal Use Only Before You Vote How to Access the Proxy Materials Proxy Materials Available to VIEW or RECEIVE: How to View Online: Have the information that is printed in the box marked by the arrow (located on the following page) and visit: www.proxyvote.com. How to Request and Receive a PAPER or E-MAIL Copy: If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request: 1) BY INTERNET: www.proxyvote.com 2) BY TELEPHONE: 1-800-579-1639 3) BY E-MAIL*: sendmaterial@proxyvote.com * If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow (located on the following page) in the subject line. g g V o t e I n P e r s o n : I f y o u c h o o s e t o v o t e t h e s e s h a r e s i n p e r s o n a t t h e m e e t i n g , y o u m u s t r e q u e s t a " l e g a l p r o x y . " T o d o s o , p l e a s e f o l l o w t h e i n s t r u c t i o n s a t w w w . p r o x y v o t e . c o m o r r e q u e s t a p a p e r c o p y o f t h e m a t e r i a l s , w h i c h w i l l c o n t a i n t h e a p p r o p r i a t e i n s t r u c t i o n s . M a n y s h a r e h o l d e r m e e t i n g s h a v e a t t e n d a n c e r e q u i r e m e n t s i n c l u d i n g , b u t n o t l i m i t e d t o , t h e p o s s e s s i o n o f a n a t t e n d a n c e t i c k e t i s s u e d b y t h e e n t i t y h o l d i n g t h e m e e t i n g . P l e a s e c h e c k t h e m e e t i n g m a t e r i a l s f o r a n y s p e c i a l r e q u i r e m e n t s f o r m e e t i n g a t t e n d a n c e . V o t e B y I n t e r n e t : T o v o t e n o w b y I n t e r n e t , g o t o w w w . p r o x y v o t e . c o m . H a v e t h e i n f o r m a t i o n t h a t i s p r i n t e d i n t h e b o x m a r k e d b y t h e a r r o w a v a i l a b l e a n d f o l l o w t h e i n s t r u c t i o n s . V o t e B y M a i l : Y o u c a n v o t e b y m a i l b y r e q u e s t i n g a p a p e r c o p y o f t h e m a t e r i a l s , w h i c h w i l l i n c l u d e a v o t i n g i n s t r u c t i o n f o r m . g 0 0 0 0 3 3 5 5 3 6 _ 2 R 1 . 0 . 1 . 1 5 1 . A n n u a l R e p o r t 2 . N o t i c e & P r o x y S t a t e m e n t R e q u e s t s , i n s t r u c t i o n s a n d o t h e r i n q u i r i e s s e n t t o t h i s e - m a i l a d d r e s s w i l l N O T b e f o r w a r d e d t o y o u r i n v e s t m e n t a d v i s o r . P l e a s e m a k e t h e r e q u e s t a s i n s t r u c t e d a b o v e o n o r b e f o r e M a y 2 8 , 2 0 1 7 t o f a c i l i t a t e t i m e l y d e l i v e r y .


BARCODE 123456789012 123456789012 123456789012 123456789012 123456789012 123456789012 123456789012 123456789012 123456789012 123456789012 123456789012 123456789012 Broadridge Internal Use Only xxxxxxxxxx xxxxxxxxxx Cusip Job # Envelope # Sequence # # of # Sequence # Voting items 0000335536_3 R1.0.1.15 The Board of Directors recommends that you vote FOR the following: 1. Election of Directors Nominees 01 Michael Gutch PhD 02 Denise Scots-Knight PhD The Board of Directors recommends you vote FOR the following proposal(s): 2. To approve an amendment to Albireo's Restated Certificate of Incorporation, as amended, to decrease the number of shares of common stock authorized for issuance from 200,000,000 to 30,000,000. 3. To ratify the appointment of Ernst & Young LLP as Albireo's independent registered public accounting firm for the fiscal year ending December 31, 2017. 4. To approve, on an advisory basis, the compensation of Albireo's named executive officers as disclosed in the proxy statement. The Board of Directors recommends you vote 3 YEARS on the following proposal: 5. To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of Albireo's named executive officers. NOTE: Such other business as may properly come before the meeting or any adjournment or postponement thereof.


THIS SPACE RESERVED FOR LANGUAGE PERTAINING TO BANKS AND BROKERS AS REQUIRED BY THE NEW YORK STOCK EXCHANGE Voting Instructions THIS SPACE RESERVED FOR SIGNATURES IF APPLICABLE P99999-010 12 15 # OF # Broadridge Internal Use Only Job # Envelope # Sequence # # of # Sequence # Reserved for Broadridge Internal Control Information 0000335536_4 R1.0.1.15

Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Albireo Pharma Charts.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Albireo Pharma Charts.